LGM Pharma, a provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, has entered the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, TX, and Colorado Springs, CO.

This investment follows the company’s previously announced $6 million expansion in Rosenberg in 2025 and is designed to increase commercial capacity, expand R&D capabilities, and support continued demand for U.S.-based drug product manufacturing.

“These multi-site investments totaling $15 million reflect our continued commitment to strengthening pharmaceutical supply chains in the United States,” said Prasad Raje, CEO of LGM Pharma. “Today’s pharma companies need partners that are both resilient and integrated across the full product lifecycle. By reinforcing domestic drug product manufacturing at the downstream end of the supply chain, closer to end markets, and leveraging our global API sourcing capabilities upstream, we create a balanced end-to-end model. This gives customers greater control and visibility as they move products from development to commercialization.”

Investment in Texas

The Texas facility enhancements include a $4 million investment to expand commercial-scale manufacturing suites for suppositories in response to increasing customer and market demand, including growth in women’s health products. The upgrades also expand R&D capabilities to support formulation and scale-up for suppositories, solutions, suspensions, and semi-solids. The Rosenberg site will remain fully operational throughout construction, with upgrades already underway.

Investment in Colorado

In Colorado Springs, LGM Pharma will invest $5 million to expand commercial manufacturing capacity for niche, high-value oral solid dose (OSD) products, including orally disintegrating tablets (ODTs). The facility has served as the company’s center of excellence for OSD development. The expansion, planned for completion this year, will support growing demand for domestic manufacturing.